199 related articles for article (PubMed ID: 32382775)
1. Pegfilgrastim improves the outcomes of mobilization and engraftment in autologous hematopoietic stem cell transplantation for the treatment of multiple myeloma.
Ding X; Huang W; Peng Y; Fan H; Zhu Y; Liu X; Yang Y; Guo Q; Qiu L; Dai Y; Zou D; Jin F
Ann Hematol; 2020 Jun; 99(6):1331-1339. PubMed ID: 32382775
[TBL] [Abstract][Full Text] [Related]
2. Pegfilgrastim- versus filgrastim-based autologous hematopoietic stem cell mobilization in the setting of preemptive use of plerixafor: efficacy and cost analysis.
Costa LJ; Kramer C; Hogan KR; Butcher CD; Littleton AL; Shoptaw KB; Kang Y; Stuart RK
Transfusion; 2012 Nov; 52(11):2375-81. PubMed ID: 22404694
[TBL] [Abstract][Full Text] [Related]
3. Pegylated Filgrastim Versus Filgrastim for Stem Cell Mobilization in Multiple Myeloma After Novel Agent Induction.
Abid MB; De Mel S; Abid MA; Yap ES; Gopalakrishnan SK; Chen Y; Yuen YC; Wong HC; Lin A; Poon LM; Koh LP; Chng WJ; Tan LK
Clin Lymphoma Myeloma Leuk; 2018 Mar; 18(3):174-179. PubMed ID: 29398647
[TBL] [Abstract][Full Text] [Related]
4. Tbo-Filgrastim versus Filgrastim during Mobilization and Neutrophil Engraftment for Autologous Stem Cell Transplantation.
Elayan MM; Horowitz JG; Magraner JM; Shaughnessy PJ; Bachier C
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1921-5. PubMed ID: 26033279
[TBL] [Abstract][Full Text] [Related]
5. Mobilization of Hematopoietic Progenitor Cells for Autologous Transplantation Using Pegfilgrastim and Plerixafor: Efficacy and Cost Implications.
Watts NL; Marques MB; Peavey DB; Innis-Shelton R; Saad A; Ad S; Salzman D; Lamb LS; Costa LJ
Biol Blood Marrow Transplant; 2019 Feb; 25(2):233-238. PubMed ID: 30219699
[TBL] [Abstract][Full Text] [Related]
6. Filgrastim-alone versus pegylated filgrastim-alone for autologous peripheral blood stem cells mobilization in newly diagnosed multiple myeloma patients.
Skopec B; Skerget M; Zontar D; Zadnik V; Zver S
Wien Klin Wochenschr; 2017 Aug; 129(15-16):545-551. PubMed ID: 28439700
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and cost of G-CSF derivatives for prophylaxis of febrile neutropenia in lymphoma and multiple myeloma patients underwent autologous hematopoietic stem cell transplantation.
Wang X; Ren J; Liang X; He P
Hematology; 2021 Dec; 26(1):950-955. PubMed ID: 34904529
[TBL] [Abstract][Full Text] [Related]
8. Comparison of CD34
Anu P; Antti T; Raija S; Marja P; Jaakko V; Timo S; Mervi P; Marja S; Anu S; Karri P; Taru K; Jukka P; Pentti M; Esa J; Ville V
Transfusion; 2021 Nov; 61(11):3202-3212. PubMed ID: 34498764
[TBL] [Abstract][Full Text] [Related]
9. Long-active granulocyte colony-stimulating factor for peripheral blood hematopoietic progenitor cell mobilization.
Martino M; Laszlo D; Lanza F
Expert Opin Biol Ther; 2014 Jun; 14(6):757-72. PubMed ID: 24597960
[TBL] [Abstract][Full Text] [Related]
10. A single dose of 6 or 12 mg of pegfilgrastim for peripheral blood progenitor cell mobilization results in similar yields of CD34+ progenitors in patients with multiple myeloma.
Bruns I; Steidl U; Kronenwett R; Fenk R; Graef T; Rohr UP; Neumann F; Fischer J; Scheid C; Hübel K; Haas R; Kobbe G
Transfusion; 2006 Feb; 46(2):180-5. PubMed ID: 16441592
[TBL] [Abstract][Full Text] [Related]
11. Comparison of filgrastim, pegfilgrastim, and lipegfilgrastim added to chemotherapy for mobilization of CD34
Partanen A; Valtola J; Ropponen A; Kuitunen H; Kuittinen O; Vasala K; Ågren L; Penttilä K; Keskinen L; Pyörälä M; Nousiainen T; Selander T; Mäntymaa P; Pelkonen J; Varmavuo V; Jantunen E
Transfusion; 2019 Jan; 59(1):325-334. PubMed ID: 30450652
[TBL] [Abstract][Full Text] [Related]
12. Tbo-filgrastim versus filgrastim for stem cell mobilization and engraftment in autologous hematopoietic stem cell transplant patients: A retrospective review.
Potter A; Beck B; Ngorsuraches S
J Oncol Pharm Pract; 2020 Jan; 26(1):23-28. PubMed ID: 30854925
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of biosimilar pegfilgrastim in patients with multiple myeloma after high-dose melphalan and autologous stem cell transplantation.
Martino M; Gori M; Porto G; Pellicano M; Santoro L; Verduci C; Canale FA; Loteta B; Moscato T; Alati C; Ieracitano MC; Cuzzocrea A; Altomonte M; Florenzano MT; Morabito A; Irrera G; Naso V; Pugliese M; Console G; Ferreri A; Imbalzano L; Tripepi G; Pitino A
Ann Hematol; 2023 Jul; 102(7):1915-1925. PubMed ID: 37079070
[TBL] [Abstract][Full Text] [Related]
14. Results of a Prospective Randomized, Open-Label, Noninferiority Study of Tbo-Filgrastim (Granix) versus Filgrastim (Neupogen) in Combination with Plerixafor for Autologous Stem Cell Mobilization in Patients with Multiple Myeloma and Non-Hodgkin Lymphoma.
Bhamidipati PK; Fiala MA; Grossman BJ; DiPersio JF; Stockerl-Goldstein K; Gao F; Uy GL; Westervelt P; Schroeder MA; Cashen AF; Abboud CN; Vij R
Biol Blood Marrow Transplant; 2017 Dec; 23(12):2065-2069. PubMed ID: 28797783
[TBL] [Abstract][Full Text] [Related]
15. Efficient mobilization of peripheral blood stem cells following CAD chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma.
Fruehauf S; Klaus J; Huesing J; Veldwijk MR; Buss EC; Topaly J; Seeger T; Zeller LW; Moehler T; Ho AD; Goldschmidt H
Bone Marrow Transplant; 2007 Jun; 39(12):743-50. PubMed ID: 17450182
[TBL] [Abstract][Full Text] [Related]
16. Long-acting granulocyte colony-stimulating factor pegfilgrastim (lipegfilgrastim) for stem cell mobilization in multiple myeloma patients undergoing autologous stem cell transplantation.
Danylesko I; Sareli R; Varda-Bloom N; Yerushalmi R; Shem-Tov N; Magen H; Shimoni A; Nagler A
Int J Hematol; 2021 Sep; 114(3):363-372. PubMed ID: 34213732
[TBL] [Abstract][Full Text] [Related]
17. Pegfilgrastim compared with filgrastim for cytokine-alone mobilization of autologous haematopoietic stem and progenitor cells.
Herbert KE; Gambell P; Link EK; Mouminoglu A; Wall DM; Harrison SJ; Ritchie DS; Seymour JF; Prince HM
Bone Marrow Transplant; 2013 Mar; 48(3):351-6. PubMed ID: 22858510
[TBL] [Abstract][Full Text] [Related]
18. Pegfilgrastim effectively mobilizes PBSC in a poor mobilizer multiple myeloma patient.
Malerba L; Mele A; Leopardi G; Stramigioli S; Politi P; Visani G
Eur J Haematol; 2006 May; 76(5):436-9. PubMed ID: 16480428
[TBL] [Abstract][Full Text] [Related]
19. EPO in combination with G-CSF improves mobilization effectiveness after chemotherapy with ifosfamide, epirubicin and etoposide and reduces costs during mobilization and transplantation of autologous hematopoietic progenitor cells.
Hart C; Grassinger J; Andreesen R; Hennemann B
Bone Marrow Transplant; 2009 Feb; 43(3):197-206. PubMed ID: 18806833
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of biosimilar granulocyte colony-stimulating factor versus originator granulocyte colony-stimulating factor in peripheral blood stem cell mobilization in de novo multiple myeloma patients.
Martino M; Recchia AG; Moscato T; Fedele R; Neri S; Gentile M; Alati C; Vincelli ID; Piro E; Penna G; Musolino C; Ronco F; Molica S; Morabito F
Cytotherapy; 2015 Oct; 17(10):1485-93. PubMed ID: 26188967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]